A detailed history of Sapient Capital LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Sapient Capital LLC holds 185,360 shares of GILD stock, worth $19.7 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
185,360
Previous 2,586 7067.83%
Holding current value
$19.7 Million
Previous $238,000 8626.47%
% of portfolio
0.41%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 15, 2025

BUY
$89.14 - $117.41 $16.3 Million - $21.5 Million
182,774 Added 7067.83%
185,360 $20.8 Million
Q4 2024

Jan 29, 2025

BUY
$83.95 - $97.9 $3,693 - $4,307
44 Added 1.73%
2,586 $238,000
Q3 2024

Oct 11, 2024

BUY
$66.59 - $83.99 $169,271 - $213,502
2,542 New
2,542 $213,000
Q4 2023

Feb 06, 2024

SELL
$73.27 - $83.09 $67,261 - $76,276
-918 Reduced 22.93%
3,086 $250 Million
Q4 2023

Jan 29, 2024

BUY
$73.27 - $83.09 $293,373 - $332,692
4,004 New
4,004 $324 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $133B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Sapient Capital LLC Portfolio

Follow Sapient Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sapient Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sapient Capital LLC with notifications on news.